134 related articles for article (PubMed ID: 19419474)
21. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials.
Korman N; Moy R; Ling M; Matheson R; Smith S; McKane S; Lee JH
Arch Dermatol; 2005 Apr; 141(4):467-73. PubMed ID: 15837864
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment of persistent melanoma in situ with 5% imiquimod cream.
Muñoz CM; Sánchez JL; Martín-García RF
Dermatol Surg; 2004 Dec; 30(12 Pt 2):1543-5. PubMed ID: 15606836
[TBL] [Abstract][Full Text] [Related]
23. Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream.
Shaffelburg M
J Drugs Dermatol; 2009 Jan; 8(1):35-9. PubMed ID: 19180894
[TBL] [Abstract][Full Text] [Related]
24. Treatment of all basal cell carcinoma variants including large and high-risk lesions with 5% imiquimod cream: histological and clinical changes, outcome, and follow-up.
Schiessl C; Wolber C; Tauber M; Offner F; Strohal R
J Drugs Dermatol; 2007 May; 6(5):507-13. PubMed ID: 17679185
[TBL] [Abstract][Full Text] [Related]
25. Selective hemangioma cell dysfunction and apoptosis triggered by in vitro treatment with imiquimod.
Rocco R; Alegre N; Pozner R; Wainstok R; Gazzaniga S
Toxicol Lett; 2018 May; 288():82-88. PubMed ID: 29410238
[TBL] [Abstract][Full Text] [Related]
26. Management of infantile hemangiomas : current and potential pharmacotherapeutic approaches.
Craiglow BG; Antaya RJ
Paediatr Drugs; 2013 Apr; 15(2):133-8. PubMed ID: 23456550
[TBL] [Abstract][Full Text] [Related]
27. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe.
Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Tebbs V; Owens M; Stampone P
Eur J Dermatol; 2005; 15(5):374-81. PubMed ID: 16172048
[TBL] [Abstract][Full Text] [Related]
28. Treatment of bowenoid and basaloid vulvar intraepithelial neoplasia 2/3 with imiquimod 5% cream.
Marchitelli C; Secco G; Perrotta M; Lugones L; Pesce R; Testa R
J Reprod Med; 2004 Nov; 49(11):876-82. PubMed ID: 15603097
[TBL] [Abstract][Full Text] [Related]
29. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.
Wolf IH; Cerroni L; Kodama K; Kerl H
Arch Dermatol; 2005 Apr; 141(4):510-4. PubMed ID: 15837872
[TBL] [Abstract][Full Text] [Related]
30. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
Neville JA; Williford PM; Jorizzo JL
J Drugs Dermatol; 2007 Sep; 6(9):910-4. PubMed ID: 17941362
[TBL] [Abstract][Full Text] [Related]
31. [Interferon alpha and infantile orbital hemangioma].
Damas Mateache B; Menéndez Suso JJ; Abelairas Gómez JM; Albajara Velasco L; Peralta Calvo J; Verdú Sánchez C; Royo Orejas A
Arch Soc Esp Oftalmol; 2003 Nov; 78(11):623-9. PubMed ID: 14648369
[TBL] [Abstract][Full Text] [Related]
32. Infantile hemangioma: clinical resolution with 5% imiquimod cream.
Martinez MI; Sanchez-Carpintero I; North PE; Mihm MC
Arch Dermatol; 2002 Jul; 138(7):881-4; discussion 884. PubMed ID: 12071813
[No Abstract] [Full Text] [Related]
33. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial.
Marks R; Gebauer K; Shumack S; Amies M; Bryden J; Fox TL; Owens ML;
J Am Acad Dermatol; 2001 May; 44(5):807-13. PubMed ID: 11312429
[TBL] [Abstract][Full Text] [Related]
34. Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week period: a case series.
Ruiz-Villaverde R; Sánchez-Cano D; Burkhardt-Pérez P
J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):828-31. PubMed ID: 19646136
[TBL] [Abstract][Full Text] [Related]
35. Infantile hemangioma: how to treat this benign neoplasm of childhood.
Schlosser KA
JAAPA; 2009 May; 22(5):46-9. PubMed ID: 19469391
[No Abstract] [Full Text] [Related]
36. Efficacy of imiquimod 5% cream for basal cell carcinoma in transplant patients.
Vidal D; Alomar A
Clin Exp Dermatol; 2004 May; 29(3):237-9. PubMed ID: 15115500
[TBL] [Abstract][Full Text] [Related]
37. The role of imiquimod in treating infantile haemangiomas: cause for concern?
Hussain W; Judge MR
Clin Exp Dermatol; 2009 Oct; 34(7):e257. PubMed ID: 19508566
[No Abstract] [Full Text] [Related]
38. [Treatment of superficial infantile hemangiomas with topical propranolol].
Niu JN; Xu GQ; Lü RR; Huo R
Zhonghua Zheng Xing Wai Ke Za Zhi; 2013 Mar; 29(2):100-3. PubMed ID: 23772486
[TBL] [Abstract][Full Text] [Related]
39. Topical timolol maleate for superficial infantile hemangiomas: an observational study.
Xu DP; Cao RY; Tong S; Xue L; Sun NN; Wang XK
J Oral Maxillofac Surg; 2015 Jun; 73(6):1089-94. PubMed ID: 25843815
[TBL] [Abstract][Full Text] [Related]
40. Treatment of an extensive superficial basal cell carcinoma of the face with imiquimod 5% cream.
Micali M; Nasca MR; Musumeci ML
Int J Tissue React; 2005; 27(3):111-4. PubMed ID: 16372477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
